Could video games boost brain and body function in Alzheimer's?
NCT ID NCT07673263
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study investigates whether playing 3D motion-sensing games (using Kinect and Google Cardboard) can improve motor control, thinking skills, and quality of life in people with mild to moderate Alzheimer's disease. Participants play specially designed games for 30 minutes a day, five days a week, for six weeks. The goal is to see if this interactive, non-drug approach offers benefits over standard care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 3D Kinect-based games and Google Cardboard virtual reality
- What this could lead to
- If effective, this approach could offer a fun, non-drug way to help people with Alzheimer's maintain motor skills, thinking ability, and quality of life.
- What could go wrong
- This is a small, early-stage study with only 38 participants, so results may not apply widely. The games may be too challenging or not engaging enough for some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 38 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Alzheimer's disease of age between 50-85 years. * Diagnosed AD stage Mild to Moderate. Exclusion Criteria: * Undiagnosed AD patients. * Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ziauddin University
Karachi, Sindhi, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a home device slow dementia? pilot trial tests pulsed electromagnetic therapy
- Can a video chat keep dementia care true to Patients' wishes?
- 10-Year watch: how safe is lecanemab outside clinical trials?
- Can a Melatonin-Like pill slow Alzheimer's memory loss?
- Could brain stimulation help Alzheimer's patients think more clearly?
- Could a common blood pressure pill recharge brain cells in Alzheimer's?